Background:
Previous studies have documented low use of evidence-based therapies for coronary artery disease (CAD) and heart failure (HF) at hospital discharge. Few studies have evaluated the extent of use of these therapies after discharge. We evaluated long term use of evidence-based therapies in CAD and HF. reported takmg both drugs.
Conclusion:
Efforts to improve the use of evidence-based therapies at hospital dlscharge are needed, but attention also needs to focus on improving long term adherence. The incidence and prevalence of chronic heart failure (CHF) are rising in the U.S., particularly in the elderly. Despite extensive comorbidity in this group, little is known about the impact of comorbidity on the economic and physician utilization burdens of CHF in these patients.
Methods:
We calculated total Medicare expenditures for each beneficwy and the number of outpatient physician visits in 1999 in a 5% nationally representatwe sample of feefor-service Medicare beneficiaries with chronic heart failure. We also assessed the incremental costs and physician utilization associated with each additional comorbidity based on ICD-9 coding?., after adjusting for patients' age, gender, race, primary provider type, and mortality dunng 1999.
Results: For the 122,620 patients in our sample, the mean age was 79.6 years. 88% wars white, and 60% were female. Mean Medicare par capita total expenditures were $17,091. Although patients with 10 or more comorbidities accounted for only 11% of the total sample, they accounted for 28% of total expenditures: with a mean of $43,439 par beneficiary. The median number of outpatient physician visits par beneficiary was 17.9. 25% of patients made 23 or more outpatient physician visits and 10% made 34 or more.
Beneficiaries with 5 or more comorbidities accounted for 73% of total outpatient visits during the year. After adjustment, each comorbidity associated with 53.668 in incremental expenditures and 2.2 in incremental outpatient visits. The Heart Failure Survival Score (HFSS) effectively risk stratifies patients for heart transplant (HT). HT can be deferred in low risk HFSS patients; patients with HFSS in the moderate and high-risk subgroups are offered HT. However, the HFSS was developed prior to broad use of beta blockade (99). We hypothesized that HFSS would retain its ability to risk stratify HT need in BB patlents. Methods: We collected clinical data on 500 consecutive patients referred for HT from 1994 to 2002. including BB and the 7 components of the HFSS: LVEF, peak V02, mean arterial BP, resting heart rate, QRS interval, serum sodium and CAD. Kaplan-M&r survival analysis with log rank testing and multivariable Cox regression analysis were performed with the events defined as death or UNOS 1 HT. Results: Kaplan-Meier analysis of the patient population (age 51+1 I, male 73%, CAD 53%, ejection fraction 2li9%, peak V02 15.8+5.1 mllminlkg, HFSS 8.02*1.02 [low risk>=8.10]) revealed effective discrimination by HFSS both for BB and no BB patients (both p<O.OOOl). Two-year event free survival was 96+2% and 87*3% for BB and no BB patients in the low-risk HFSS strata. Cox proportional hazards modeling showed that both BB (RR 0.48, p = 0.0001) and the HFSS (p c 0.0001) at the time of HT evaluatwn were independently associated with event-free survival. Conclusion: HFSS provides effective risk stratification with or without 99. Consideration of BB therapy with HFSS strata improves outcome predictlon in patients evaluated for HT.
Conclusion

